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ess: tzortzaki@med.uocSummary Recently DNA mismatch repair system (MMR) has been extensively
investigated in molecular medicine. Microsatellite (MS) DNA alterations are
considered as indicating an ineffective MMR system. MS loss of heterozygosity
(LOH) and microsatellite instability (MSI) have been reported in a number of human
malignancies.
LOH and MSI have recently been detected in benign diseases, such as actinic
keratosis, pterygium and aterosclerosis. In addition, MSI and LOH have been
detected in asthma, chronic obstructive pulmonary disease, sarcoidosis and
idiopathic pulmonary fibrosis. This is a review of MSI in benign lung diseases.
It is concluded that detecting genetic alterations at the MS DNA level could be a
useful technique to identify locus of potential altered genes that may play a key role
in the pathogenesis of these diseases. In addition, MSI and LOH could be used as a
genetic screening tool in molecular epidemiology.
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Genomic microsatellite (MS) also known as simple
sequences repeats (SSRs), are iterations of 1–6 bp
nucleotide motifs and have been detected in
prokaryotic and eukaryotic cells.1–4 They are
present in both coding and non-coding regions of
the chromosome. They constitute a rather large
fraction of non-coding DNA and are relatively rare
in protein-coding regions.3,4
Numerous evidences available today suggest that
MSs genomic distribution is non-random across
coding and non-coding regions. Although MSs are
usually considered just as evolutionary neutral DNA
markers, the functional significance of a small but
substantial part of MS has been proven by critical
tests to take part in various biological phenomena
such as gene transcription, translation, chromatin
organization, recombination, DNA replication, DNA
mismatch repair system (MMR), cell cycle and
others.5–10 MSs are characterized by high levels of
polymorphism, whose origin appears most likely to
be due to slippage events during DNA replication
although this is still under debate.11
With the use of polymerase chain reaction (PCR)
technology MS DNA was converted into a highly
versatile genetic marker.12 MS have proven to be an
extremely valuable tool for genome mapping in
many organisms, but their applications span over
different areas ranging from forensic DNA studies to
degraded DNA studies (e.g. museum material),
population genetics and conservation/management
of biological resources.12–14 In addition, it could be
used as a genetic screening tool in studies of
molecular epidemiology.13,15Microsatellite DNA instability and loss of
heterozygosity (MSI and LOH)
The most common MS in humans is a dinucleotide
repeat of cytosine and adenine, (CA)n, which
occurs in tens of thousands of locations in the
germ line. Trinucleotide repeats are prone to
expansion in meiosis, and when abnormally ex-
panded they lead to a variety of neurologic
disorders and fragile chromosomal sites (the fragile
X syndrome).6,12,13,16,17
Genetic instability can be subdivided into chro-
mosomal instability (CIN) and microsatellite in-
stability (MSI), the latter being due to mutations in,or silencing of DNA-MMR genes, namely, MLH1,
MSH2, PMS1, PMS2 and MSH6 (Fig. 1).16
The genomic MS is associated with high mutation
rates, as compared with the rates of mutation at
coding gene loci.18 The mutation process differs
among repeat types, loci and alleles, species, age
and sex.19–21
Two mechanisms can be invoked to explain such
high rates of mutation. The first involves DNA
slippage during replication and the second, recom-
bination between DNA strands.22,23 Interestingly,
strains with and without a functional recombination
system had a very similar mutation rate, suggesting
that recombination is not the predominant me-
chanism generating MS variability.24 MSs are parti-
cularly prone to slippage during replication, that is,
the number of base repeats in the newly replicated
strand may differ from the original, thus resulting
in a small loop in either the template or the new
DNA strand.25–27 DNA MMR system contributes to
genomic stability by surveillance and repairing the
replication errors (Fig. 2). Dysfunction of the MMR
system can lead to the loss of chromosomal stability
that might play a role in carcinogenesis.28–31
Microsatellite instability and human
carcinogenesis
Two distinct forms of genetic instability are
presently recognized in neoplastic cells, one being
CIN which leads to aneuploidy and the other being
MSI, which occurs due to frequent errors that occur
during the replication of short nucleotide repeats
(Fig. 1).32,33 Among the genes that play a key role
in multistage carcinogenesis are the tumor sup-
pressor genes (TSGs). It has been shown that loss of
genetic material in one allele (LOH) may poten-
tially lead to cancer.32
MSI was first described in the Lynch syndrome
(hereditary non-polyposis colorectal cancer),32,33
whereas germ-line mutations in the MMR genes
MLH1, MSH2, MSH6, and PMS2 lead to the develop-
ment of the syndrome. This phenomenon has since
been implicated in about 15% of sporadic colorectal
cancers, as well as several other sporadic malig-
nancies such as lung, gastric, endometrial, ovarian,
breast, prostate, bladder, head and neck, and
melanoma.33–46
Several chromosomal regions exhibiting genetic
alterations have been studied in human lung
cancer. LOH on chromosome 8p is an early
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Figure 1 The two forms of genetic instability.
K. Samara et al.204molecular change in the development of lung
cancer.47 Other areas of frequent allelic losses
include chromosomes 1p, 3p, 5p, 9p, 9q, 13q, 17p,
and 17q.38,48–50Microsatellite instability and loss of
heterozygosity in benign extra-pulmonary
diseases
It has been shown that a number of neurological
disorders showed expansion of unstable trinucleo-
tide repeats (triplet expansion). Such diseases are
the fragile X syndrome, myotonic dystrophy, Hun-
tington’s disease, the Machado Joseph disease and
others.51–53
Apart from triplet expansion, other classes of MSs
were also found to be associated with human
diseases. Length polymorphism of the aldose
reductase gene is associated with diabetic retino-
pathy, and (CA)n allele polymorphism in the human
interferon-g gene is associated with lung allograft
fibrosis.54,55
Furthermore, the phenomenon of LOH and/or MSI
has been found often in ocular pterygium, actinic
keratoses and human atherosclerotic plaques.56–58
LOH appears to be a common finding in psoriaticplaques, providing evidence for deletion of regula-
tory genes59; it is also displayed in the pseudoexfo-
liation syndrome which is characterized by the
accumulation of a material of unknown origin in the
anterior structures of the eye.60
MSI and suppressed DNA repair enzyme expres-
sion due to oxidative stress has been demonstrated
in rheumatoid arthritis synovial tissue.61 MSI is also
a detectable phenomenon in some azoospermic
men, predominantly in Sertoli cell-only syndrome
patients,62 in spontaneously aborted embryonic
tissues63 and finally in pancreatic serous micro-
cystic adenomas, a rare benign tumor with a
striking female preference.64Microsatellite instability and loss of
heterozygosity in benign pulmonary disease
There is evidence suggesting that common respira-
tory diseases such as COPD and asthma showed
genetic predisposition and are probably multigenic.
In order to further investigate the genetic back-
ground of these diseases the MS DNA has been used
as genetic screening tool.65–70 Sputum cells65–69 or
bronchial epithelium71 was used to detect MSI. As
MSI was detected in patients with lung cancer,38 it
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Microsatellite DNA instability in benign lung diseases 205was successfully attempted to investigate its
appearance in patients with COPD,65,66 asthma,67
sarcoidosis68 and idiopathic pulmonary fibrosis,69
using sputum samples.
The presence of MSI and/or LOH was detected in
MS DNA extracted from cytological samples (spu-
tum). DNA extraction was performed from sputum
cells and peripheral whole blood (white blood cells)
of the same individual. PCR was then carried out to
amplify the DNA sequences. The MSI and/or LOH
were scored by comparing the electrophoretic
pattern of the MS markers amplified from the
paired DNA preparations (sputum/WBCs) as a shift
of one or both of the alleles in the pathologic DNA
specimen, or as a generation of novel alleles
indicated by the addition or the deletion of one
or more repetitive units. Typical electrophoresis of
the MS stability and MSI are shown in Fig. 3.microsatellite instability in the D6S344 marker. (B)
Leukocyte-extracted DNA; (S) sputum-extracted DNA;
(MSS) microsatellite stability; (MSI) microsatellite in-
stability.COPD
Spandidos et al.65 first showed that MSI is a
detectable phenomenon in COPD. Siafakas et al.66
investigated MSI or/and LOH in induced sputumcells from 59 severe COPD patients and 60 smokers
without COPD. A set of MS markers were used,
including markers next to genes for irreversible
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Figure 4 Serum immunoglobulin E (IgE) and blood
eosinophils in Group I (asthmatics with less than 3
genetic alterations (I)). Group II (asthmatics with three
or more genetic alterations (II)), and control subjects
(III). See text for details. (Modified from Paraskakis et
al.64)
K. Samara et al.206airway obstruction and cancer in chromosome areas
3p21.1–p14.2, 6p22–24, 8p21.1–q11.2, 11q, 13q32
and 17q21.65 The authors showed that 14 out of 59
(24%) COPD patients exhibited MSI in their sputum
sample. In 10 patients, one MS marker was found to
be unstable; in the remaining 4 patients, instability
was detected in two different MS markers. The
most commonly affected marker was THRA1 on
chromosome 17 (43%). The fact that only 24% of the
COPD patients exhibited MSI, could be explained as
only 8 MS markers were investigated.66
No significant differences were found between
MSI-positive and MSI-negative COPD patients for
clinical or laboratory parameters, survival and lung
cancer development. No change in the MS alleles
was found when the same tests were performed
within a 24-month interval.66
The above results supported the hypothesis that
MSI could be part of the complex genetic basis of
COPD, revealing chromosomal areas of genetic
alteration. Recently, Anderson and Bozinovski72 ad-
vanced the hypothesis that acquired somatic muta-
tions caused by cigarette smoke are a fundamental
contributor to the molecular pathogenesis of COPD.
The susceptibility to acquiring such mutations, might
be controlled by inherited genes, such as those
encoding genes that detoxify inhaled mutagens.72
Another possible hypothesis could be that MSI
reflects a defect in the repair process of DNA,
caused by the oxidative stress of cigarette smoking
that leads to an inappropriate remodeling of the
airways. Smoking is thought to cause potentially
irreversible genetic changes in the epithelial cells.
Therefore the substantial and significant reduction
in all-cause mortality in people with mild to
moderate airway obstruction after smoking cessa-
tion, are probably due to the absence of further
insult rather than to reversal of existing disease.73
Moreover, given the higher risk to suffer from
lung cancer in the presence of COPD as well as the
bad prognostic effect of COPD in lung cancer
patients74 it could be useful to early detect
acquired genetic events, including alterations in
TSGs in preneoplastic lesions, including metaplasia
and dysplasia as it was shown by Kohno et al.75Asthma
In order to investigate whether genetic defects
such as MSI and/or LOH are detectable phenomena
in asthma, Paraskakis et al.67 used sputum samples
from 22 patients with moderate asthma and 8 with
severe persistent asthma. Eighteen highly poly-
morphic MS markers located on chromosome areas5q, 6p, 11q, and 14q were investigated. The
selection of these chromosomal regions was based
on knowledge that these regions contain genes
expressing cytokines, mediators and receptors,
postulated to be candidate genes for atopy and
asthma.70,71,76–79 Genetic alterations were found in
16 out of 22 (73%) moderate asthmatic patients and
3 out of 8 (38%) severe asthmatics. Twelve patients
(54.5%) exhibited LOH alone, 1 patient (4.5%) MSI
only, while 3 patients (13.6%) exhibited both LOH
and MSI. The marker most frequently affected
exhibiting LOH was D14S292 (23%), whereas for MSI
it was the D14S588 marker (13.6%). Both markers
were found on chromosome 14q. Moreover, Para-
skakis et al. divided the asthmatic patients into 2
groups, the first with few genetic alterations (0–2,
Group I) and the second with more alterations (43,
Group II). Mean immunoglobulin E and blood
eosinophils levels were significantly higher in
asthmatics with 3 or more genetic alterations
(Fig. 4). The high frequency of genetic alterations
detected at the MS level in loci of genes controlling
the inflammation and bronchial hyperresponsive-
ness associated with altered phenotypic elements
of allergy and asthma (increased IgE and eosino-
phils) indicated that those loci may play a role in
the pathogenesis of asthma, though further studies
are needed to clarify the significance of the LOH
and MSI in asthma.67COPD vs. asthma
Based on previous studies 65–67 Zervou et al.80
recently attempted to investigate similarities
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Figure 5 Moderate COPD group with similar mean FEV1
with asthma group exhibited significant higher MSI
frequency.
Microsatellite DNA instability in benign lung diseases 207or/and differences at the MS DNA level in COPD and
asthmatic patients. Specific MS markers to cross-
check the incidence of MSI in both diseases were
used to identify if there are common or disease-
specific MSI patterns between COPD and asthma.
Induced sputum from 63 COPD patients, 17
patients with moderate to severe asthma and 9
healthy individuals as control group, were ana-
lyzed. Specific regions of chromosomes 3p, 5q, 6p,
13q, 14q, 17q harboring: (a) susceptibility genes for
asthma and allergy, (b) genes associated with a
higher risk of developing irreversible airway ob-
struction, were analyzed. The authors reported
that certain loci appeared to be specific for COPD,
while 1 marker expressed instability in both
diseases. None of the MS markers tested appeared
to be asthma specific. In addition, it was demon-
strated that COPD patients showed significantly
higher MSI frequency compared with the asthma
group (Fig. 5). MSI was not detected at the control
group.80
Although these are preliminary results, Zervou
et al.80 implicate that genetic alterations detected
by the instability of MSs, may differentiate asthma
from COPD at the MS DNA level.Sarcoidosis
The incidence of MSI and LOH, was also investi-
gated in interstitial lung diseases such as sarcoi-
dosis.68,81,82 Sarcoidosis is a multisystem disease
characterized by the occurrence in affected organs
of non-caseating granulomatous lesions which may
progress to cause fibrosis. The etiology is unknown
but the accumulation of T4-helper lymphocytes at
disease sites is suggestive of an immunologicalreaction. The organ most frequently affected is the
lung.83 Unlike many diseases in which the lung is
involved, sarcoidosis is more common in non-
smokers.84–86 Nonetheless, it has been observed
that there is a slightly higher incidence for
sarcoidosis patients to develop malignancies, in-
cluding lung cancer.87–90
Vassilakis et al.68 found that 14 of 30 (47%)
sarcoidosis patients showed genetic alterations,
either MSI or LOH in at least 1 of the 10 markers
studied. The most commonly affected MS markers
were ANK1 on chromosome 9p (20%), THRA1 on
chromosome 17q (13.3%) and D9S59 on chromo-
some 9q (11.5%).68 The authors concluded that the
precise significance of these findings remains
obscure, because the information regarding the
genetic basis of the disease is limited. However,
they speculated that the relatively high mutational
rate of sarcoidosis patients, as reflected in the
instability of the MS sequences, indicates a desta-
bilization of the genome and might be implicated in
the etiopathogenesis of the disease.68 Moreover,
the authors82 investigated the incidence of MSI in
markers located in or close to DNA MMR genes,
hMSH2 and hMLH1 as well as in CD48 and IRF4,
genes associated with lymphocyte activation. They
concluded that genomic instability in sarcoidosis
could be due to MMR defects, while alterations of
lymphocyte-specific agents could account for gran-
uloma formation.82Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis is a serious disease of
unknown etiology. It is probably the result of the
inflammatory and immune response of the lung to
tissue damage.91 Bronchogenic carcinoma is the
cause of death in 10–13% of IPF patients.92,93 Ten
MS markers located in chromosomes 8p, 9p, 9q and
17q were used by Vassilakis et al. to investigate
genetic alterations in IPF.69 The selection of
chromosome regions was based on previous studies
concerning either lung cancer or benign lesions of
the lung such as COPD.39,65,66 They reported that 13
out of 26 (50%) IPF patients manifested either MSI
or LOH, in at least 1 of the studied markers.69 The
most commonly affected MS markers were THRA1
on chromosome 17q and D8S133 regarding MSI and
D8S133 and ANK1 on chromosome 9p regarding
LOH. A significant incidence of LOH, in 4 of 24
specimens (17%), was found at the locus
8p21.3–q11.1 (marker D8S133). The authors sug-
gested that important TSGs for the development of
IPF may be located in this chromosomal region.
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Figure 6 Summary of microsatellite instability (MSI) and loss of heterozygosity (LOH) in COPD, IPF, sarcoidosis, asthma
and in ‘‘healthy’’ smokers and non-smokers.
K. Samara et al.208Deletions at 8p21.3–q11.2 occur frequently in lung
neoplasms.94,95 The authors concluded that fine
mapping of these areas is required in order to
establish the precise location of the candidate
TSG(s) and their role in the pathogenesis of IPF.
The above results were confirmed in a larger
study by Demopoulos et al.96 where 52 sputum
samples from IPF patients were investigated using
40 highly polymorphic MS DNA markers. LOH was
found in 20 (38.5%) patients in at least 1 locus.
These alterations were found on markers previously
associated with lung cancer located on 1p34.3,
3p21.32–p21.1, 5q32–q33.1, 9p21 and 17p13.1
where MYCL1, FHIT, SPARC, p16(Ink4) and TP53
genes have been mapped, respectively.96Toward a new concept for microsatellite
DNA instability in benign lung diseases
In the past, MSs were considered useful only as
genetic markers. However, MSs can have a func-
tional role in the genome, affecting gene expres-
sion by acting as regulatory sequences that can be
recognized by transcription factors10,18,97 or possi-
bly by acting as shields to protect DNA fromenvironmental hazards, e.g tobacco smoke.10,18,98
These results are in agreement with the above
hypothesis that gives a functional role in the MS
DNA.10,18,29,97,98 Detecting genetic alterations at
the MS DNA level could be a useful technique to
identify the locus of potential altered genes that
may play a key role in various benign diseases’
pathogenesis.66–69
It is of great importance to point out that all 125
healthy control subjects, both smokers and non-
smokers, tested for MSI or LOH in the above
mentioned studies, did not exhibit any genetic
alteration.66–69 The fact that LOH or MSI were not
detected in the normal subjects support the
hypothesis that these are disease-specific altera-
tions. A summary of MSI in benign lung diseases is
presented in Fig. 6. Finally, the importance of
studying disease-associated specific genetic mar-
kers is highlighted.Acknowledgements
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